Inicio
Explorar
nav.journalClub
Tendencias
Más
Synapse
⌘+K
Synapse
Idioma
Español
Español
Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire. | Synapse
March 14, 2026
Ver artículo completo
Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire.
YH
Yasuhiro Hamatani
Heart Failure / Cardiomyopathy
AP
Alexander Peikert
Heart Failure & Transplant
BC
Brian L Claggett
Brigham and Women's Hospital
Ver todo
Puntos clave
To assess the impact of finerenone on quality of life in heart failure patients using the Kansas City Cardiomyopathy Questionnaire.
Analysis of component-level outcomes from the Kansas City Cardiomyopathy Questionnaire.
Utilization of clinical data from the clinical trial NCT04435626.
Improvements in quality of life scores among heart failure patients on finerenone treatment.
Clinical relevance established through detailed component-level analyses.
Resumen
ClinicalTrials.gov ID NCT04435626.
Preguntar a la IA
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Ver artículo completo
Preguntar a la IA
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Ver artículo completo
Cite This Study
Copy
Hamatani et al. (Thu,) studied this question.
synapsesocial.com/papers/69b4b9fb18185d8a398025cf
https://doi.org/https://doi.org/10.1093/ejhf/xuag062